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Abstract
Patients with severe viral infections are often hospitalized in intensive care units (ICUs) and recent studies underline the
frequency of viral detection in ICU patients. Viral infections in the ICU often involve the respiratory or the central nervous
system and can cause significant morbidity and mortality especially in immunocompromised patients. The mainstay
of therapy of viral infections is supportive care and antiviral therapy when available. Increased understanding of the
molecular mechanisms of viral infection has provided great potential for the discovery of new antiviral agents that target
viral proteins or host proteins that regulate immunity and are involved in the viral life cycle. These novel treatments need
to be further validated in animal and human randomized controlled studies.
Introduction
The prevalence of viral diseases has increased due to the
availability of modern diagnostic tests that allow rapid
detection of viruses [1]. Viral diseases may additionally
be associated with significant morbidity and mortality as
is the case with some emerging viral diseases, such as
the Middle East Respiratory Syndrome coronavirus or
avian influenza [2,3]. Patients with severe viral infections
are often hospitalized in intensive care units (ICUs); on
the other hand recent studies have underlined the fre-
quency of virus detection in ICU patients [4-6]. The ma-
jority of viral infections that require ICU care involve
the respiratory tract or the central nervous system. How-
ever, other organ systems, such as the gastrointestinal
tract, may be severely affected by viruses and require
support or close monitoring. The reported incidence of
viral infections reported in the ICU varies widely across
studies and geographic regions and has changed over
the recent years based on the epidemiology of emerging
viral infections such as human metapneumovirus and
adenovirus infections [7,8]. Improved molecular detec-
tions methods have also significantly changed the epi-
demiology of viral infections in the ICU over the last
years [7]. Multi-institutional databases and time-series
models may be useful tools to characterize and forecast
the burden of severe viral infections at the local and in-
stitutional levels [9,10]. Clinical signs and symptoms are
rarely sufficient to make a specific diagnosis of a viral in-
fection. Often a combination of the appropriate clinical
syndrome together with epidemiologic clues but more
importantly specific laboratory tests is used to reach the
diagnosis [11]. Viral infections can cause severe morbid-
ity and mortality in certain hosts such as immunocom-
promised patients (Table 1) [12-52]. Herein, we review
the literature on the role of viruses in ICU in adults [ex-
cluding Human Immunodeficiency Virus (HIV)] with a
focus on treatment of these infections.
Review
Respiratory infections
In recent years, viruses have been identified as an in-
creasingly frequent cause of community-acquired pneu-
monia (CAP) [53], because of the availability of new
diagnostic tools, such as Polymerase Chain Reaction
(PCR). On the other hand the emergence of the pan-
demic influenza virus in 2009 as well as the emergence
of viruses with pandemic potential such as the avian in-
fluenza viruses or new coronaviruses has emphasized the
role of viruses in severe community acquired pneumonia
in places where these viruses are endemic [54]. Viral
nosocomial pneumonia [hospital-acquired, healthcare-
associated pneumonia (HCAP) or ventilator-associated
pneumonia (VAP)] have been described but the patho-
genicity and the roles of viruses recovered from the
lower respiratory tract in patients with pneumonia
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Table 1 Etiologies and treatment of viral syndromes in the ICU
Syndrome/presentation Common viruses Treatment
RESPIRATORY FAILURE
Hypoxic respiratory failure-pneumonia Hypoxic respiratory failure: Influenza A and B,
RSV A and B, coronavirus, Severe Acute Respiratory
Syndrome (SARS), Middle East Respiratory
Syndrome coronavirus, Adenovirus,
cytomegalovirus, Varicella, HSV, Parainfluenza 1-4,
Metapneumovirus, measles especially in
immunocompromised patients
Supportive: adequate oxygen delivery
VAP: HSV, CMV, Mimivirus
Hypercapnic-hypoxic respiratory failure Hypercapnic-hypoxic respiratory failure:
Influenza A and B, coronavirus, rhinovirus,
Parainfluenza 1-4, RSV A and B
Antivirals:
Asthma/COPD exacerbation Neuraminidase inhibitors (NAIs) (Oseltamivir,
Zanamivir, peramivir, Laninamivir) [12,13]. For
resistant influenza viruses may consider
combination therapy of NAI with ribavirin and/
or novel antivirals such as Favipiravir [14,15]
Adult Respiratory Distress Syndrome (ARDS) ARDS: Influenza virus, Hantavirus [Hantavirus
pulmonary syndrome (HPS)], varicella, herpes
simplex virus, SARS, MERS-CoV
Ribavirin for RSV in immunocompromised
patients and children [16-18] and may also be
considered for other viruses such as in SARS [25]
or MERS-CoV - lopinavir in combination
regimens has also been used
Without lung disease (restrictive disease):
Guillain-Barré syndrome (GBS)
GBS: HSV, VZV, CMV, EBV, Influenza, Hantavirus
acute and chronic hepatitis B, Rare causes: West
Nile virus, Parvovirus B19, Hantavirus, rubella,
dengue
Acyclovir for VZV pneumonitis (limited efficacy it
is still widely recommended as early primary
therapy) [19]
Ganciclovir for CMV pneumonitis in solid organ
transplant patients appears to reduce morbidity
[20]
Corticosteroids: For influenza [21-23], SARS
[24,25] and VZV pneumonitis [26] to reduce
inflammatory tissue injury in severe pneumonia
Immunotherapies: Palivizumab is approved for
high-risk pediatric patients with RSV infection
[18]; IVIG for certain respiratory viruses including
influenza [27,28] and GBS, plasma exchange for
GBS. Combinations of ganciclovir with immuno-
globulin or cytomegalovirus immunoglobulin
may be of value in patients with bone marrow
transplants and CMV pneumonitis [29,30]
Others: Vitamin A for severe measles [31]
Neurological syndromes
Encephalitis, meningitis, meningoencephalitis,
myelitis, polyradiculo-neuropathy, Guillain-Barré
syndrome (GBS) Reyes syndrome, subacute
sclerosing panencephalitis, postinfectious acute
disseminated encephalomyelitis (ADEM) [32]
HSV (40% to 50% of encephalitis cases where a
cause is determined, and 10% to 20% overall
[32] VZV (the most common cause of
encephalitis among immunocompromised
patients and the second most common viral
cause of sporadic encephalitis not occurring
during an outbreak)
Supportive: Treatment of neurologic (eg,
cerebral edema, high intracranial pressure, and
seizures) and systemic (eg, hypoxemia, low
cerebral perfusion pressure, and fever)
complications
Clinical presentation: usually as altered mental
status, seizures, coma, neuropathies
Enteroviruses (Enterovirus 71, Coxsackie, Echovirus,
poliovirus: as a group, enteroviruses) are
collectively the third most common cause of
sporadic viral encephalitis and the most
common cause of aseptic meningitis
Antivirals:
Acyclovir: Early aggressive antiviral therapy with
acyclovir for HSV, VZV improves mortality and
reduces subsequent cognitive impairment
Arboviruses (JEV, WNV, TBEV, MVEV, LCEV, SLEV,
EEEV: the most common pathogens to cause
encephalitis that is restricted to certain
geographic regions)
Influenza (encephalitis is very uncommon
complication of seasonal influenza infections but
because influenza itself is common 4-19% of
patients with severe or fatal H1N1 reported
neurologic complications
Ganciclovir: CMV encephalitis
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Table 1 Etiologies and treatment of viral syndromes in the ICU (Continued)
Other viruses: West Nile virus, CMV, mumps,
measles, rubella, rabies, JC virus (PML),
acute HIV infection)
Foscarnet: HHV-6, combination therapy with
foscarnet and ganciclovir is recommended
for CMV encephalitis
Oseltamivir: Severe influenza
Pleconaril: severe Enterovirus infections
Corticosteroids: Complicated HSV encephalitis
(data based on retrospective studies), VZV
encephalitis (for inflammatory vasculopathy),
uncomplicated zoster (variable results), severe
influenza, WNV (case report) [33], postinfectious
encephalitis
Immunotherapies: Immunomodulatory
therapy with either intravenous immune
globulin or plasma exchange for patients
with postinfectious encephalitis who fail
corticosteroid treatment (data based on
case series) or for WNV encephalitis
(Case reports) [34,35].
Others: Vitamin A for severe measles [31]
Virus related shock
Cardiogenic shock Enteroviruses (Enterovirus 71, Coxsackie viruses
group A and B, Echovirus), Influenza, Adenovirus,
Parvovirus, RSV, CMV, HIV-1, hepatitis A and C
viruses, vaccinia virus (after smallpox vaccine)
Supportive
Myocarditis Antivirals:
Rifampin: For RSV myocarditis [36]
Pleconaril: severe Enterovirus infections
Oseltamivir: Severe influenza
ART: HIV-1
Corticosteroids: do not reduce mortality (data
based on small RCT of poor quality) [37]
Immunotherapies: IVIG (data based on in vitro
data, case series, limited RCT) [38-40].
Combination therapy of IVIG with rifampin has
been described in case series [36]
Others: Herbal medicines [41], mechanical
ventricular assist devices until resolution or
cardiac transplantation is available, novel
therapies e.g pleconaril
Distributive shock-Hemorrhagic fever Arenaviruses (South American HF-Junin; Lassa
Fever), Bunyaviruses (Rift valley fever, Chrimean
Congo HF-CCHF), HF with renal syndrome,
Hantavirus, Filoviruses (Ebola, Marburg),
Flaviviruses (Yellow fever, Dengue HF)
Supportive: adequate oxygen delivery, blood
products.
Clinical presentation: Febrile illnesses,
headache, myalgia, nausea, vomiting and
diarrhea are frequent. Hemorrhagic features,
disseminated intravascular coagulopathy (DIC),
multiple organ system failure and death ensue.
Passive transfer of antibodies (plasma, IVIG)
may be of value in Bunyaviruses [45], Junin virus
[42], Lassa virus [43], Hantavirus HF [17,44],
Flaviviruses (Yellow fever, Dengue HF) [45-47]
Antivirals: ribavirin for CCHF [17,48], Lassa virus
[17,49], Hantavirus HF [17,44]
Ribavirin plus interferon may be considered for
Lassa virus [50]
Hypovolemic/distributive shock in the
setting of acute liver failure secondary to
viral hepatitis
Hepatitis A, B, C, D, E, G, herpes group
(CMV, HSV and Epstein Barr virus),
adenovirus and influenza virus
Supportive: hemodynamic management,
ventilation, prevention and treatment of
hemorrhage, dialysis, therapy of co-existent
sepsis and electrolyte disturbance, and
management of intracranial pressure
Clinical presentation: Nausea and vomiting
with progression to encephalopathy and coma;
may be new onset or acute decompensation
of chronic liver failure due to viral hepatitis/
cirrhosis
Orthotopic liver transplantation
Antivirals (may be used for acute flare up
of chronic viral hepatitis e.g. in
immunocompromised patients.
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remains controversial. Severe viral infections such as in-
fluenza, severe acute respiratory syndrome (SARS) may
cause respiratory failure which may rapidly progress to
acute respiratory distress syndrome (ARDS) and multi-
organ failure [55-58]. Except for pneumonia, acute respira-
tory failure can occur in patients with chronic obstructive
pulmonary disease (COPD) and lead to hospitalization and
the need for mechanical ventilation [55-58]. In addition,
viruses can cause ARDS and neurogenic respiratory
failure (for example through development of Guillain-Barré
Syndrome) [55-58].
Causes of viral pneumonia
Respiratory viruses are the most common cause of viral CAP
Although severe community-acquired pneumonia is usually
caused by bacteria, viruses account for approximately 3-
10% of cases in large series [59-65]. The most common
cause of viral pneumonia in adults is influenza virus type A
and B [32,53,65-73]. Immunocompromised patients are
more likely to have viral pneumonias caused by respiratory
syncytial virus (RSV), cytomegalovirus (CMV), herpes sim-
plex virus (HSV), varicella-zoster virus (VZV), adenovirus
and rarely measles (21-35). Recent molecular diagnostic
methods have significantly changed the epidemiology of
viral pneumonias in the ICU over the last years with the in-
creasing detection of viruses such as human metapneumo-
virus and adenovirus infections [7,8]. Radiographic findings
are variable and not virus specific; an “atypical” pneumonia
presentation is often seen in otherwise healthy individuals
while on the other hand severe lobar or bilateral pneumo-
nia can be seen in immunocompromised hosts. All the
reported respiratory viruses can cause severe pneumonia
with acute respiratory distress syndrome (ARDS) requiring
mechanical ventilation, but the frequency of this complica-
tion is not known [55-58].
Respiratory viruses may be the cause of HCAP
Viral pneumonias may be nosocomially acquired, especially
during peak respiratory periods and in immunocomprom-
ised patients [74-76]. In a recent retrospective study,
34% of the 134 HCAP patients had at least one respira-
tory virus recovered either in the lower respiratory
tract or the nasopharyngeal swab [77], with the most
frequent being rhinovirus, parainfluenza virus, human
Metapneumovirus and influenza. Patients with viral HCAP
or bacterial VAP had the same mortality rate [77].
Table 1 Etiologies and treatment of viral syndromes in the ICU (Continued)
Hypovolemic/distributive shock in the
setting of acute pancreatitis
Mumps (the most common virus associated with
pancreatitis, occurring even in the absence of
parotitis), Enteroviruses (Coxsackie B),
cytomegalovirus, varicella zoster, HSV-1, Epstein-
Barr virus, influenza A, Parainfluenza, adenovirus,
measles. In fulminant hepatic failure due to
hepatitis A (HAV) or hepatitis E (HEV) pancreatitis
occurs in up to 34% of the cases [51]
Supportive
Antivirals
Oseltamivir: Severe influenza
Pleconaril: severe Enterovirus infections
Acyclovir: VZV
Shock in the setting of adrenal insufficiency
caused by viral infection (rare)
CMV in HIV-1 infection [52] Treatment of CMV itself is generally not
warranted, unless there is evidence of CMV
disease elsewhere. However, it is critical to treat
the underlying human immunodeficiency virus
infection with antiretroviral agents to attempt
immune restitution [52]
Rhabdomyolysis Influenza A and B, Parainfluenza virus, CMV, EBV,
VZV, measles, adenovirus, enteroviruses
Supportive
Antivirals
Oseltamivir: Severe influenza
Pleconaril: Severe Enterovirus infections
Acyclovir: VZV
Ganciclovir: CMV
Special Immunocompromised host
Trauma/Burn HSV, CMV Supportive, antivirals, corticosteroids
Pregnancy HSV, VZV, CMV, Influenza virus Supportive, antivirals
Transplantation CMV, EBV [post-transplant lymphoproliferative
disorder (PTLD)], VZV, HSV, HHV-6 and HHV-8,
RSV, Influenza A and B, BK virus, Adenovirus
Supportive, antivirals, immunotherapies (for
example donor lymphocyte infusions and anti-
CD20 antibody for PTLD), experimental therapies
Abbreviations: ADEM acute disseminated encephalomyelitis, Adult Respiratory Distress Syndrome (ARDS), CMV Cytomegalovirus, CCHF Chrimean Congo
Hemorrhagic Fever, COPD Chronic Obstructive Pulmonary Disease, DIC disseminated intravascular coagulopathy, EBV Epstein Barr virus, Guillain-Barré syndrome
(GBS), HAV hepatitis A virus, HBV hepatitis B virus, HCV hepatitis C virus, or HEV hepatitis E virus, HIV human immunodeficiency virus, HHV-6 Herpes Virus 6, HHV-8
Herpes Virus 8, HF Hemorrhagic Fever, HSV Herpes Simplex Virus, NAIs Neuraminidase inhibitors, ICU Intensive Care Unit, JEV Japanese Encephalitis Virus, MVEV
Murray Valley encephalitis virus, PTLD post-transplant lymphoproliferative disorder, RCT Randomized Controlled trials, RSV Respiratory Syncytial Virus, SARS Severe
Acute Respiratory Syndrome, TBEV tick-borne encephalitis virus, SLEV St. Louis Encephalitis Virus, VZV Varicella-Zoster Virus, WNV West Nile virus.
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Mostly latent viruses, particularly Herpesviridae, are
identified in patients with VAP
Although data on viral nosocomial pneumonia are
scarce, the role of respiratory viruses as a cause of
nosocomial pneumonia is probably limited. In two
studies in ICU patients, <5.5% of mechanically venti-
lated patients with VAP had a respiratory sample posi-
tive for respiratory viruses [6,72,78] and in many of
these cases the mechanical ventilation duration before
virus detection may have indicated carriage before ICU
admission. Latent viruses such as Herpesviridae in-
cluding herpes simplex virus (HSV) and cytomegalo-
virus (CMV) are known to be a cause of pneumonia or
systemic disease in immunocompromised patients [79]
but are often reactivated in non-immunocompromised
ICU patients. ICU patients are known to experience
immunoparalysis since an initial proinflammatory is
followed by an anti-inflammatory response; this im-
munological state is responsible for nosocomial infec-
tions and latent virus reactivation [80,81]. In most
patients, viral detection reflects viral reactivation with-
out lung parenchymal involvement. However, viral
lung disease may develop, usually in patients with pro-
longed mechanical ventilation [6,82,83]. Mimivirus, an
emergent virus, has also been described as a possible
cause for nosocomial VAP [84-88]. Although patients
with high HSV and CMV viremia often have worse
prognosis, the exact significance of detection of HSV,
CMV or mimivirus in the lower respiratory tract of
ventilated non-immunocompromised ICU patients is un-
clear [4-6,72,82,83,89]. Further clinical research work is
needed to elucidate the role of these viruses in the patho-
genesis of nosocomial viral pneumonia.
Treatment of viral respiratory infections
Treatment of viral CAP remains largely supportive
Influenza is the only virus for which Food and Drug
Administration (FDA)-approved therapeutic agents are
available for adults. The most effective measure against
influenza remains vaccination, particularly for the elderly
or high-risk individuals [90]. Antivirals for the treatment
of influenza include the M2 channel inhibitors and the
neuraminidase inhibitors [91]. Although treatment with
neuraminidase inhibitors (oseltamivir or zanamivir) is
recommended in all patients with suspected or con-
firmed influenza requiring hospitalization [92] their use
in non-severe influenza could be more harmful than
beneficial because of the possibility of selection of resist-
ant mutants [93]. Thus, it would be appropriate to use
them only for patients with severe disease presentation,
for example, severe pneumonia, requiring mechanical
ventilation or patients at high risk for influenza associ-
ated complications e.g immunocompromised individuals.
Alternatively it can be used in all suspect cases in areas
endemic for a strain with high mortality e.g. an avian
influenza strain. Higher dosing regimens such as 150 mg
twice daily may be safe and well tolerated [94-98], have
been used to treat seriously ill patients [58,99,100] and
may have a benefit for treatment of Influenza B [101],
some influenza A strains with reduced susceptibility
[12,102-106] as well as infection sites with limited drug
penetration (eg, central nervous system, as in some
H5N1 cases) [96,98,107,108]. However, overall support-
ive evidence is lacking [91,94,95,99,101,102,109-111] and
antiviral resistance may emerge even with higher doses
of oseltamivir [112].
Novel antivirals can be considered for treatment of
respiratory viral infections
Two new neuraminidase inhibitors have recently been
described: peramivir and laninamivir octanoate. Perami-
vir, which can be given as a single intravenous dose, was
authorized for a short period by the US Food and Drug
Administration (FDA) for emergent intravenous use in
hospitalized patients with the 2009 H1N1 pandemic in-
fluenza virus [113]. Laninamivir is given as a single in-
haled dose for the treatment of seasonal influenza in
adults and may also treat oseltamivir-resistant virus
[113]. In addition, new therapeutics for the treatment of
influenza A virus infections are under development
[13-15,18,28,39,50,114-195]. In this regard, the drug,
favipiravir (T-705) has been shown to inhibit a variety of
influenza viruses, including highly pathogenic avian in-
fluenza H5N1 viruses. Finally, numerous antivirals such
as entry inhibitors, nucleoside analogues such as cidofo-
vir, viral enzyme inhibitors (such as terminase and heli-
case enzyme inhibitors), and translation inhibitors may
be utilized in an off-label indication for treatment of
viral infections [13,113].
Combination antiviral therapy can be used for treatment of
resistant influenza
Except for HIV, hepatitis C and hepatitis B, combination
drug therapies are not established for other viruses, such
as HSV and influenza. Triple and dual drug combina-
tions may be synergistic in their antiviral action [196].
The efficacy of oseltamivir-zanamivir combinations for
seasonal influenza was established in a randomized con-
trolled clinical study [188]. However, clinical antagonism
between oseltamivir and zanamivir was suggested in an-
other study [188,193].
Other therapies for treatment of influenza
Low-dose systemic corticosteroids may be used for sep-
tic shock related to severe influenza [58] since evidence
from RCTs suggests that corticosteroids may be associ-
ated with delayed clearance of viruses [21-23] and inva-
sive fungal infections [197]. Case control studies and a
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RCT suggested that plasma and hyperimmune globulin
have demonstrated favorable responses in patients with
severe avian influenza A (H5N1) and H1N1pdm09 infec-
tion compared with controls [27,28,198]. Further evalu-
ation of novel treatments with RCTs is needed.
Viral infections of the nervous system in the ICU
Several viruses may infect the central nervous system
(CNS) and cause inflammation of the meninges and
brain parenchyma causing meningitis, encephalitis,
seizures, coma and respiratory failure, secondary to
aspiration, neuromuscular weakness and increasing
atelectasis [32].
The etiology of meningoencephalitis is often not identified
Several viruses may cause infectious and postinfectious
complications in the nervous system (Table 1). Despite
advances in molecular techniques a specific cause is
found in less than half of the cases [32].
Modern ICU care has significantly improved prognosis of
viral nervous system infections
Acyclovir has significantly improved the prognosis of
HSV encephalitis. Although without treatment, the
mortality was more than 70% and has now decreased
to <20% [32], many of the survivors have persisting
neurological deficits. The prognosis of other viral en-
cephalitides is generally comparable to that of HSV en-
cephalitis [32].
Treatment of viral infections of the nervous system
Supportive therapy is the mainstay of treatment of viral
nervous system infections
Neurologic and systemic complications may exacerbate
brain damage and should be identified and treated early
with supportive therapy to optimize neurologic recovery
(Table 1). Evidence from RCTs is lacking and thus corti-
costeroids should not be used routinely; they may be
used in selected cases with significant edema, in postin-
fectious encephalitis and in VZV encephalitis [32].
Early administration of antivirals is key for treatment of
herpetic viral infections
The drug of choice for the treatment of HSV encephal-
itis is high-dose intravenous acyclovir which should be
administered as early as possible for 14 to 21 days. A
clinical trial is currently assessing longer courses of ther-
apy using oral valacyclovir [32]. There are no clinical tri-
als regarding the use of antivirals for VZV encephalitis
[32] but acyclovir for up to 3 weeks is recommended for
severe infections like encephalitis. A longer course of
therapy may be considered for immunocompromised
patients. Foscarnet is the preferred agent against HHV-
6 whereas combination therapy with foscarnet and
ganciclovir is recommended as initial treatment of
CMV encephalitis (Table 1).
The use of antivirals is limited in non-herpetic viral nervous
system infections
Antivirals have not been proven effective for enterovirus
encephalitis. The drug pleconaril is an inhibitor of viral
replication and may be an option for patients with se-
vere Enterovirus infections [32]. Use of oseltamivir is ap-
propriate for severe influenza. There is also no specific
treatment for most causes of encephalitis although ex-
perimental therapies may be considered [13,113].
Viral causes of shock in the ICU
Viral myocarditis can cause cardiogenic shock
Numerous viruses can cause viral myocarditis, including
Coxsackie viruses group A and B (Table 1) [41]. Most
patients recover, but persistent cardiac dysfunction is as-
sociated with 20% one-year mortality [199]. The majority
of patients with acute myocarditis have evidence of heart
failure. In severe cases mechanical ventricular assist
device support is necessary until resolution or cardiac
transplantation is available [199]. Although immunosup-
pressive medicines including corticosteroids were applied
in many studies with viral myocarditis, meta-analyses have
shown that their effects remain controversial since
they do not reduce mortality [37]. In a systematic re-
view, the use of intravenous immunoglobulins (IVIGs)
in viral myocarditis was not recommended [38]. Ex-
perimental strategies for treatment of viral myocarditis
have been developed [13,113,200].
Viral Hemorrhagic Fevers (VHF) can cause distributive shock
Viral hemorrhagic fevers (VHF) are caused by RNA vi-
ruses. The main vectors involved in transmission are
and rodents or arthropods (Table 1). The clinical syn-
drome of hemorrhagic fever is secondary to capillary
leakage due to increased vascular permeability. Other
clinical manifestations depend on the virus involved and
include, hepatitis, encephalitis, and/or nephropathy as well
as multiorgan failure. Disseminated intravascular coagulop-
athy (DIC) is one of the common characteristic findings to
many but not all of these viruses. There is a wide range of
case-fatality rates that may vary from 1% to 90% [113]. Im-
mediate isolation is critical for effective infection control
and prevention of transmission in suspect cases. Close col-
laboration with local and national public health authorities
is necessary to alert the community of a possible outbreak
[113]. Since there are no effective therapeutic interventions
for most of the viruses the care is largely supportive. No
corticosteroids should be used. There are no antiviral drugs
available for the treatment of hemorrhagic fever viruses,
and there is only one vaccine widely available, i.e. the yellow
fever 17D vaccine. Ribavirin has been reported to be an
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effective therapy for Lassa fever [49], but not against
other hemorrhagic fever virus infections in humans [113].
Specific immune human plasma has been successful in
treating certain hemorrhagic fevers such as the Argentinian
hemorrhagic fever [42]. Emerging therapies with activity
against VHF including Ebola have been described and are
under development [13,113,201,202].
Other important considerations regarding treatment of
viral infections in the ICU
Infection control measures have a major role in the
management of viral infections in the ICU
The primary factor responsible for transmission of viral
infections in the ICU seems to be inadequate training in
or compliance with infection control procedures
[203,204]. The use of nebulizers, open suctioning of re-
spiratory secretions, the use of Bi-PAP, endotracheal in-
tubation, outdated ventilation systems may also lead to
spread of viral infections in the ICU setting [203,204].
Infection control measures should include airborne,
droplet and contact precautions. Disinfectants are highly
active against many viruses [203,204].
Vaccines are not adequate in preventing the spread of
many viral infections in the ICU
Vaccination is possible to prevent infections with some
viruses: influenza A and B viruses, HBV, varicella-zoster
virus, Yellow fever virus and poliovirus. However vac-
cines are not available for major viral infections such as
herpes simplex virus (HSV) and antiviral therapy is
needed to control viral infections that cannot be pre-
vented by vaccination.
Numerous antiviral drugs are undergoing clinical trials
The emergence of resistant viruses underlines the need
to find novel antiviral. A few novel strategies have been
introduced for antiviral research but further research is
needed before they can be used for treatment of drug-
resistant viral infections [13,113].
Targeting latency may lead to complete treatment of
chronic latent infections
Despite effective antiviral therapy for certain chronic
viral infection (e.g. Hepatitis B), the virus can integrate
its genome into the host cell and become latent. There-
fore, new therapies that can completely remove viral
components integrated in host cells are needed [13,113].
Conclusion
Patients with severe viral infections are often hospitalized
in intensive care units (ICUs). Viral infections can cause se-
vere morbidity and mortality in certain hosts (Table 1)
[4-6]. The mainstay of therapy of viral infections is support-
ive care. Antiviral therapy is available for a limited number
of infections including influenza and herpetic infections.
Novel antiviral treatments that target viral proteins (mostly
involved in enzymatic activities or in the viral replication
machinery) or host proteins that regulate immunity or
other cellular processes in host cells and are involved in the
viral life cycle need to be further validated in animal and
human randomized controlled studies.
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